Conferences and presentations

On Friday May 17th, 2024, CTO Nikolaj Skak had the pleasure to present the BIONDD™ technology at the TIDES USA Conference in Boston.

Great to see large audience and high level of interest in our BIONDD™ technology. The technology offers a platform for delivering biologics orally through a standard capsule. This technology ensures that the biologic drug molecule is precisely targeted to the stomach wall for safe and effective release into the body.

Take a look at the technology at Biograil™ – Welcome to Biograil

. . .



On February 27th 2024, Karsten Lindhardt CEO and founder of Biograil had the pleasure of presenting the BIONDD™ technology to an exclusive audience at the CEO & Investor Conference in NYC.

Take a look at the technology at Biograil™ – Welcome to Biograil


. . .



I am happy to share that, I have finalized my project “Assessment of barriers towards oral treatment of autoimmune diseases with adalimumab” by presenting my research to colleagues at Biograil™, March 7th, 2024.

The project was part of my education at Syddansk Universitet – University of Southern Denmark, where I got the opportunity to combine a disease related ailment with potential pharmaceutical treatment.

The project represents the potential of innovative treatment with BIONDD™ in patients suffering from Crohn’s disease.
The project was conducted in collaboration with Biograil™ and Syddansk Universitet – University of Southern Denmark. A special thank you to my supervisors Nina Mertz and Søren Fisker Schmidt, who believed in this project from the beginning.

. . .

CTO Nikolaj Skak and Industrial Postdoc Nina Mertz attended the APPSComms PharmsSci 360 October 22-25, 2023, in Orlando, FL.

It was great to see that drug-delivery combination products were a well-represented topic at the conference and discussed at several sessions and keynote speeches.

It made it all the more exciting to add to the discussions with our poster and a Rapid Fire talk on the BIONDD™ technology for oral delivery of biologics.

. . .